display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
es-BC - TNBC - NA - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons